» Articles » PMID: 24700780

Solution Structure of the Major Factor VIII Binding Region on Von Willebrand Factor

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2014 Apr 5
PMID 24700780
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Although much of the function of von Willebrand factor (VWF) has been revealed, detailed insight into the molecular structure that enables VWF to orchestrate hemostatic processes, in particular factor VIII (FVIII) binding and stabilization in plasma, is lacking. Here, we present the high-resolution solution structure and structural dynamics of the D' region of VWF, which constitutes the major FVIII binding site. D' consists of 2 domains, trypsin-inhibitor-like (TIL') and E', of which the TIL' domain lacks extensive secondary structure, is strikingly dynamic and harbors a cluster of pathological mutations leading to decreased FVIII binding affinity (type 2N von Willebrand disease [VWD]). This indicates that the backbone malleability of TIL' is important for its biological activity. The principal FVIII binding site is localized to a flexible, positively charged region on TIL', which is supported by the rigid scaffold of the TIL' and E' domain β sheets. Furthermore, surface-charge mapping of the TIL'E' structure reveals a potential mechanism for the electrostatically guided, high-affinity VWF⋅FVIII interaction. Our findings provide novel insights into VWF⋅FVIII complex formation, leading to a greater understanding of the molecular basis of the bleeding diathesis type 2N VWD.

Citing Articles

How Electricity Prevents Us from Bleeding to Death.

McCaig C Rev Physiol Biochem Pharmacol. 2025; 187():115-145.

PMID: 39838012 DOI: 10.1007/978-3-031-68827-0_11.


Heyde Syndrome Unveiled: A Case Report with Current Literature Review and Molecular Insights.

Maksic M, Corovic I, Stanisavljevic I, Radojevic D, Veljkovic T, Todorovic Z Int J Mol Sci. 2024; 25(20).

PMID: 39456826 PMC: 11507012. DOI: 10.3390/ijms252011041.


Von Willebrand factor and hematogenous cancer metastasis under flow.

Xu W, Tan X, Li M, Xu H, Villegas J, Fu H Front Cell Dev Biol. 2024; 12:1435718.

PMID: 39282473 PMC: 11401050. DOI: 10.3389/fcell.2024.1435718.


Mechano-covalent protection of coagulation factor VIII by von Willebrand factor.

Butera D, Wang H, Woon H, Zhao Y, Ju L, Hogg P Blood Adv. 2022; 7(10):2117-2128.

PMID: 36240294 PMC: 10196764. DOI: 10.1182/bloodadvances.2022008650.


A conformational transition of the D'D3 domain primes von Willebrand factor for multimerization.

Gruber S, Lof A, Hausch A, Kutzki F, Johr R, Obser T Blood Adv. 2022; 6(17):5198-5209.

PMID: 36069828 PMC: 9631632. DOI: 10.1182/bloodadvances.2022006978.


References
1.
Hansen D, Neudecker P, Vallurupalli P, Mulder F, Kay L . Determination of Leu side-chain conformations in excited protein states by NMR relaxation dispersion. J Am Chem Soc. 2009; 132(1):42-3. DOI: 10.1021/ja909294n. View

2.
Tuddenham E, Lane R, Rotblat F, Johnson A, Snape T, Middleton S . Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol. 1982; 52(2):259-67. DOI: 10.1111/j.1365-2141.1982.tb03888.x. View

3.
Bax A, Kontaxis G, Tjandra N . Dipolar couplings in macromolecular structure determination. Methods Enzymol. 2001; 339:127-74. DOI: 10.1016/s0076-6879(01)39313-8. View

4.
Allen S, Abuzenadah A, Blagg J, Hinks J, Nesbitt I, Goodeve A . Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood. 2000; 95(6):2000-7. View

5.
Hampshire D, Goodeve A . The international society on thrombosis and haematosis von Willebrand disease database: an update. Semin Thromb Hemost. 2011; 37(5):470-9. DOI: 10.1055/s-0031-1281031. View